Journal article
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas
Blood cancer journal (New York), Vol.14(1), 172
10/09/2024
DOI: 10.1038/s41408-024-01145-0
PMCID: PMC11464677
PMID: 39384745
Abstract
This study sheds light on the pivotal role of the oncoprotein DEK in B-cell lymphoma. We reveal DEK expression correlates with increased tumor proliferation and inferior overall survival in cases diagnosed with low-grade B-cell lymphoma (LGBCL). We also found significant correlation between DEK expression and copy number alterations in LGBCL tumors, highlighting a novel mechanism of LGBCL pathogenesis that warrants additional exploration. To interrogate the mechanistic role of DEK in B-cell lymphoma, we generated a DEK knockout cell line model, which demonstrated DEK depletion caused reduced proliferation and altered expression of key cell cycle and apoptosis-related proteins, including Bcl-2, Bcl-xL, and p53. Notably, DEK depleted cells showed increased sensitivity to apoptosis-inducing agents, including venetoclax and staurosporine, which underscores the therapeutic potential of targeting DEK in B-cell lymphomas. Overall, our study contributes to a better understanding of DEK's role as an oncoprotein in B-cell lymphomas, highlighting its potential as both a promising therapeutic target and a novel biomarker for aggressive LGBCL. Further research elucidating the molecular mechanisms underlying DEK-mediated tumorigenesis could pave the way for improved treatment strategies and better clinical outcomes for patients with B-cell lymphoma.
Details
- Title: Subtitle
- DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas
- Creators
- Melissa A Hopper - Mayo Clinic in ArizonaAbigail R Dropik - Mayo Clinic in ArizonaJanek S Walker - Mayo Clinic in ArizonaJoseph P Novak - Mayo Clinic in ArizonaMiranda S Laverty - Mayo ClinicMichelle K Manske - Mayo Clinic in ArizonaXiaosheng Wu - Mayo Clinic in ArizonaKerstin Wenzl - Mayo Clinic in ArizonaJordan E Krull - Mayo Clinic in ArizonaVivekananda Sarangi - Mayo Clinic in FloridaMatthew J Maurer - Mayo Clinic in FloridaZhi-Zhang Yang - Mayo Clinic in ArizonaMiles D Del Busso - Mayo ClinicThomas M Habermann - Mayo Clinic in ArizonaBrian K Link - University of IowaLisa M Rimsza - Mayo Clinic HospitalThomas E Witzig - Mayo ClinicStephen M Ansell - Mayo Clinic in ArizonaJames R Cerhan - Mayo Clinic in FloridaDragan Jevremovic - Mayo Clinic in ArizonaAnne J Novak - Mayo Clinic in Arizona
- Resource Type
- Journal article
- Publication Details
- Blood cancer journal (New York), Vol.14(1), 172
- DOI
- 10.1038/s41408-024-01145-0
- PMID
- 39384745
- PMCID
- PMC11464677
- NLM abbreviation
- Blood Cancer J
- ISSN
- 2044-5385
- eISSN
- 2044-5385
- Publisher
- SPRINGERNATURE
- Grant note
- T32AI170478 / U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P50 CA97274 / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) T32AI007425 / U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01 CA212162 / NCI NIH HHS
- Language
- English
- Date published
- 10/09/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984722715802771
Metrics
4 Record Views